{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:19:32Z","timestamp":1763367572048,"version":"3.44.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.mcna.2022.10.016","type":"journal-article","created":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T23:12:02Z","timestamp":1672614722000},"page":"329-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ovarian, Uterine, and Vulvovaginal Cancers"],"prefix":"10.1016","volume":"107","author":[{"given":"Deborah Gomez","family":"Kwolek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Gerstberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Tait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanna M.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2022.10.016_bib1","series-title":"Sex- and gender-based women\u2019s health","first-page":"231","article-title":"Gynecologic malignancies","author":"Prifti","year":"2020"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","article-title":"Epithelial ovarian cancer: An overview","volume":"3","author":"Desai","year":"2014","journal-title":"World J Transl Med"},{"issue":"23","key":"10.1016\/j.mcna.2022.10.016_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","article-title":"Inflammation and ovarian cancer","volume":"58","author":"Maccio","year":"2012","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.mcna.2022.10.016_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/cancers10080251","article-title":"The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer","volume":"10","author":"Savant","year":"2018","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1530\/ERC-11-0107","article-title":"The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer","volume":"18","author":"King","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"7716","key":"10.1016\/j.mcna.2022.10.016_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation\u2014a factor in ovarian neoplasia","volume":"298","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"9609","key":"10.1016\/j.mcna.2022.10.016_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib13","first-page":"212","article-title":"Symptoms of ovarian cancer","volume":"98","author":"Olson","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"22","key":"10.1016\/j.mcna.2022.10.016_bib14","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.22371","article-title":"Development of an ovarian cancer symptom index: possibilities for earlier detection","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","article-title":"Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial","volume":"193","author":"Buys","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajog.2008.01.005","article-title":"Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis","volume":"198","author":"Kurman","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A\u00a0randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"22","key":"10.1016\/j.mcna.2022.10.016_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"10022","key":"10.1016\/j.mcna.2022.10.016_bib20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib21","first-page":"593","article-title":"Accuracy of the pelvic examination in detecting adnexal masses","volume":"96","author":"Padilla","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijgo.2004.09.015","article-title":"Limitations of the pelvic examination for evaluation of the female pelvic organs","volume":"88","author":"Padilla","year":"2005","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"10.1016\/j.mcna.2022.10.016_bib23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.2016.12819","article-title":"Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"317","author":"Guirguis-Blake","year":"2017","journal-title":"JAMA"},{"issue":"433","key":"10.1016\/j.mcna.2022.10.016_bib24","doi-asserted-by":"crossref","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.","volume":"319","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.mcna.2022.10.016_bib27","series-title":"StatPearls","article-title":"Ovarian cancer","author":"Arora","year":"2022"},{"key":"10.1016\/j.mcna.2022.10.016_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bpobgyn.2016.10.007","article-title":"Surgery for advanced epithelial ovarian cancer","volume":"41","author":"Hacker","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2022.10.016_bib30","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.mcna.2022.10.016_bib31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_8","key":"10.1016\/j.mcna.2022.10.016_bib32","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.mcna.2022.10.016_bib34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2022.10.016_bib35","first-page":"CD004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","volume":"3","author":"Winter-Roach","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mcna.2022.10.016_bib36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2022.10.016_bib37","first-page":"CD005343","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","volume":"8","author":"Morrison","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0000000000000592","article-title":"Latest clinical evidence of maintenance therapy in ovarian cancer","volume":"32","author":"Walsh","year":"2020","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib40","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1758834012467661","article-title":"Bevacizumab and ovarian cancer","volume":"5","author":"Garcia","year":"2013","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","article-title":"Bevacizumab toxicities and their management in ovarian cancer","volume":"117","author":"Randall","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.mcna.2022.10.016_bib43","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2022.10.016_bib44","first-page":"114","article-title":"Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO","volume":"66","author":"Klar","year":"2016","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib45","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3892\/mco.2017.1266","article-title":"Factors favouring long-term survival following recurrence in ovarian cancer","volume":"7","author":"Soyama","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.12.421","article-title":"A\u00a0study of symptoms described by ovarian cancer survivors","volume":"125","author":"Stavraka","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib49","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/0284186X.2012.689111","article-title":"Diagnosis and treatment of sarcoma of the uterus. A review","volume":"51","author":"Trope","year":"2012","journal-title":"Acta Oncol"},{"year":"2022","series-title":"NCCN clinical practice guidelines in oncology: uterine Neoplasms, version 1.2022","key":"10.1016\/j.mcna.2022.10.016_bib51"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib53","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/AOG.0000000000004711","article-title":"Executive summary of the uterine cancer evidence review conference","volume":"139","author":"Chelmow","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"2 Pt 1","key":"10.1016\/j.mcna.2022.10.016_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/AOG.0b013e3182605bf1","volume":"120","author":"Sorosky","year":"2012","journal-title":"Endometrial Cancer Obstet Gynecol"},{"issue":"7447","key":"10.1016\/j.mcna.2022.10.016_bib55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.mcna.2022.10.016_bib56","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrc3967","article-title":"Adiposity and cancer risk: new mechanistic insights from epidemiology","volume":"15","author":"Renehan","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib57","first-page":"38","article-title":"American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001\u2013testing for early lung cancer detection","volume":"51","author":"Smith","year":"2001","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.mcna.2022.10.016_bib58","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib59","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jpag.2019.06.004","article-title":"Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger","volume":"32","author":"Rosen","year":"2019","journal-title":"J\u00a0Pediatr Adolesc Gynecol"},{"issue":"11","key":"10.1016\/j.mcna.2022.10.016_bib60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J\u00a0Gen Intern Med"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib61","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"601: Tamoxifen and uterine cancer","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-8258(03)00441-4","article-title":"Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen","volume":"91","author":"Fung","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005820115535","article-title":"Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients","volume":"47","author":"Bertelli","year":"1998","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib64","first-page":"468","article-title":"Diagnosis and Management of Endometrial Cancer","volume":"93","author":"Braun","year":"2016","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib65","first-page":"14","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"7","key":"10.1016\/j.mcna.2022.10.016_bib66","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bjc.2014.407","article-title":"Association between diabetes, diabetes treatment and risk of developing endometrial cancer","volume":"111","author":"Luo","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib67","first-page":"129","article-title":"Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"62","author":"Smith","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0032-1313780","article-title":"Endometrial and ovarian cancer in lynch syndrome","volume":"25","author":"Crispens","year":"2012","journal-title":"Clin Colon Rectal Surg"},{"issue":"16","key":"10.1016\/j.mcna.2022.10.016_bib69","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2010.32.9979","article-title":"Testing women with endometrial cancer to detect Lynch syndrome","volume":"29","author":"Kwon","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib70","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00404-012-2492-2","article-title":"Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC\/Lynch syndrome (LS)","volume":"286","author":"Manchanda","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2013.2","article-title":"The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium","volume":"108","author":"Felix","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib72","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1438.2007.01025.x","article-title":"The risk of developing uterine sarcoma after tamoxifen use","volume":"18","author":"Lavie","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib73","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00000421-199602000-00013","article-title":"Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies","volume":"19","author":"Mark","year":"1996","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.mcna.2022.10.016_bib75","first-page":"1407","article-title":"The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women","volume":"24","author":"Cote","year":"2015","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib76","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.amjmed.2008.01.044","article-title":"Cigarette smoking and the risk of endometrial cancer: a meta-analysis","volume":"121","author":"Zhou","year":"2008","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.contraception.2020.06.008","article-title":"Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: A retrospective cohort study of Danish women","volume":"102","author":"Iversen","year":"2020","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib79","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib80","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0002-9378(95)90483-2","article-title":"Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding\u2013a Nordic multicenter study","volume":"172","author":"Karlsson","year":"1995","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.mcna.2022.10.016_bib81","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1720::AID-CNCR19>3.0.CO;2-6","article-title":"CA 125 may not reflect disease status in patients with uterine serous carcinoma","volume":"82","author":"Price","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib82","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0002-9378(90)90400-2","article-title":"Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma","volume":"162","author":"Patsner","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib83","first-page":"12","article-title":"Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma","volume":"84","author":"Rose","year":"1994","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib84","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A\u00a0comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib86","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2017.05.027","article-title":"Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations","volume":"146","author":"Holloway","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.mcna.2022.10.016_bib87","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.2011.38.8645","article-title":"Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study","volume":"30","author":"Walker","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib89","doi-asserted-by":"crossref","first-page":"266.e1-12","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.mcna.2022.10.016_bib90","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mcna.2022.10.016_bib91","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.mcna.2022.10.016_bib92","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib93","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mcna.2022.10.016_bib95","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.mcna.2022.10.016_bib96","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib97","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A\u00a0nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib98","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1148\/radiol.2016160200","article-title":"Utility of PET\/CT to evaluate retroperitoneal lymph node metastasis in high-risk endometrial cancer: results of ACRIN 6671\/GOG 0233 trial","volume":"283","author":"Atri","year":"2017","journal-title":"Radiology"},{"issue":"48","key":"10.1016\/j.mcna.2022.10.016_bib99","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.15585\/mmwr.mm6748a1","article-title":"Uterine Cancer Incidence and Mortality - United States, 1999-2016","volume":"67","author":"Henley","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.mcna.2022.10.016_bib101","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.2105\/AJPH.94.12.2104","article-title":"Endometrial cancer: socioeconomic status and racial\/ethnic differences in stage at diagnosis, treatment, and survival","volume":"94","author":"Madison","year":"2004","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib102","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2013.05.020","article-title":"Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States","volume":"130","author":"Long","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ygyno.2017.01.024","article-title":"Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis","volume":"145","author":"Bregar","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib104","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/AOG.0000000000000605","article-title":"Racial disparities in treatment of high-grade endometrial cancer in the Medicare population","volume":"125","author":"Rauh-Hain","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"22","key":"10.1016\/j.mcna.2022.10.016_bib105","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1200\/JCO.2003.01.218","article-title":"Differences in treatment and outcome between African-American and white women with endometrial cancer","volume":"21","author":"Randall","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib106","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2011.02.004","article-title":"Racial disparities in surgical care for uterine cancer","volume":"121","author":"Fleury","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib107","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.ajog.2020.02.041","article-title":"Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment","volume":"223","author":"Kaspers","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib108","doi-asserted-by":"crossref","first-page":"396.e1","DOI":"10.1016\/j.ajog.2020.02.021","article-title":"Impact of quality of care on racial disparities in survival for endometrial cancer","volume":"223","author":"Huang","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0000000000004424","article-title":"Racial-ethnic and socioeconomic disparities in guideline-adherent treatment for endometrial cancer","volume":"138","author":"Rodriguez","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/AOG.0000000000004710","article-title":"Health disparities in uterine cancer: report from the uterine cancer evidence review conference","volume":"139","author":"Whetstone","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"32","key":"10.1016\/j.mcna.2022.10.016_bib111","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007751","article-title":"Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint","volume":"96","author":"Yagi","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib112","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ygyno.2007.11.011","article-title":"Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States","volume":"108","author":"Stroup","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib113","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2020.08.036","article-title":"Management and outcomes of primary vaginal Cancer","volume":"159","author":"Yang","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.mcna.2022.10.016_bib114","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/cncr.23759","article-title":"Incidence of in\u00a0situ and invasive vulvar cancer in the US, 1998-2003","volume":"113","author":"Saraiya","year":"2008","journal-title":"Cancer"},{"issue":"10 Suppl","key":"10.1016\/j.mcna.2022.10.016_bib115","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.23757","article-title":"Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States","volume":"113","author":"Wu","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib116","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.2010.192","article-title":"Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma","volume":"24","author":"HP","year":"2011","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.mcna.2022.10.016_bib117","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/ijc.30821","article-title":"Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva","volume":"141","author":"Faber","year":"2017","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib118","first-page":"222","article-title":"Vaginal and cervical abnormalities after exposure to stilbestrol in utero","volume":"102","author":"Pitkin","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.mcna.2022.10.016_bib119","doi-asserted-by":"crossref","unstructured":"Committee Opinion No.675: Management of Vulvar Intraepithelial Neoplasia published correction appears in Obstet Gynecol. 2017. Obstet Gynecol. 2016;128(4):e178\u2013e182.","DOI":"10.1097\/AOG.0000000000001713"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.critrevonc.2014.09.002","article-title":"Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors","volume":"93","author":"Gadducci","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib121","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00404-015-3835-6","article-title":"Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia","volume":"293","author":"Jentschke","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib123","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2012.12.032","article-title":"Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States","volume":"129","author":"Tergas","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2022.10.016_bib124","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/AOG.0000000000001033","article-title":"Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors","volume":"126","author":"Chase","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2022.10.016_bib125","first-page":"S97","article-title":"Cancer of the vagina","volume":"119","author":"Hacker","year":"2012","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib126","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.critrevonc.2011.04.004","article-title":"Vaginal cancer","volume":"81","author":"Di Donato","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib127","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/1097-0142(20000701)89:1<116::AID-CNCR16>3.0.CO;2-4","article-title":"Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study","volume":"89","author":"Maggino","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mcna.2022.10.016_bib130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.canlet.2006.09.003","article-title":"Prediction of persistent vaginal intraepithelial neoplasia in previously hysterectomized women by high-risk HPV DNA detection","volume":"249","author":"Frega","year":"2007","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.mcna.2022.10.016_bib131","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.mcna.2022.10.016_bib132","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ygyno.2005.03.006","article-title":"Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva","volume":"97","author":"Gonzalez Bosquet","year":"2005","journal-title":"Gynecol Oncol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712522001584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712522001584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:47:12Z","timestamp":1758419232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712522001584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0025712522001584"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2022.10.016","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian, Uterine, and Vulvovaginal Cancers","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2022.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}